Literature DB >> 18063750

Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation.

Paria Mirmonsef1, Gladys Tan, Gang Zhou, Tricia Morino, Kimberly Noonan, Ivan Borrello, Hyam I Levitsky.   

Abstract

Immune reconstitution of autologous hematopoietic stem-cell transplant recipients with the progeny of mature T cells in the graft leads to profound changes in the emerging functional T-cell repertoire. In the steady state, the host is frequently tolerant to tumor antigens, reflecting dominant suppression of naive and effector T cells by regulatory T cells (T(regs)). We examined the relative frequency and function of these 3 components within the tumor-specific T-cell compartment during immune reconstitution. Grafts from tumor-bearing donors exerted a significant antitumor effect in irradiated, syngeneic tumor-bearing recipients. This was associated with dramatic clonal expansion and interferon-gamma (IFNgamma) production by previously tolerant tumor-specific T cells. While donor-derived T(regs) expanded in recipients, they did not inhibit the antigen-driven expansion of effector T cells in the early posttransplantation period. Indeed, the repopulation of tumor-specific effector T cells significantly exceeded that of T(regs), the expansion of which was limited by IL-2 availability. Although the intrinsic suppressive capacity of T(regs) remained intact, their diminished frequency was insufficient to suppress effector cell function. These findings provide an explanation for the reversal of tolerance leading to tumor rejection in transplant recipients and likely contribute to the efficacy of adoptive T-cell therapies in lymphopenic hosts.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18063750      PMCID: PMC2234051          DOI: 10.1182/blood-2007-06-096586

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

1.  Interleukin-2-dependent mechanisms of tolerance and immunity in vivo.

Authors:  Paul A Antony; Chrystal M Paulos; Mojgan Ahmadzadeh; Akgül Akpinarli; Douglas C Palmer; Noriko Sato; Andrew Kaiser; Christian S Hinrichs; Christian Heinrichs; Christopher A Klebanoff; Yutaka Tagaya; Nicholas P Restifo
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

2.  CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

Authors:  Sergio A Quezada; Karl S Peggs; Michael A Curran; James P Allison
Journal:  J Clin Invest       Date:  2006-06-15       Impact factor: 14.808

Review 3.  Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).

Authors:  Bruce R Blazar; William J Murphy
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

4.  Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.

Authors:  Gang Zhou; Charles G Drake; Hyam I Levitsky
Journal:  Blood       Date:  2005-09-22       Impact factor: 22.113

5.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Richard M Sherry; Suzanne L Topalian; Nicholas P Restifo; Richard E Royal; Udai Kammula; Don E White; Sharon A Mavroukakis; Linda J Rogers; Gerald J Gracia; Stephanie A Jones; David P Mangiameli; Michelle M Pelletier; Juan Gea-Banacloche; Michael R Robinson; David M Berman; Armando C Filie; Andrea Abati; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

6.  Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells.

Authors:  Hua Zhang; Kevin S Chua; Martin Guimond; Veena Kapoor; Margaret V Brown; Thomas A Fleisher; Lauren M Long; Donna Bernstein; Brenna J Hill; Daniel C Douek; Jay A Berzofsky; Charles S Carter; E J Read; Lee J Helman; Crystal L Mackall
Journal:  Nat Med       Date:  2005-10-16       Impact factor: 53.440

7.  Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.

Authors:  Aaron P Rapoport; Edward A Stadtmauer; Nicole Aqui; Ashraf Badros; Julio Cotte; Lisa Chrisley; Elizabeth Veloso; Zhaohui Zheng; Sandra Westphal; Rebecca Mair; Nina Chi; Bashi Ratterree; Mary Francis Pochran; Sabrina Natt; Joanne Hinkle; Cheryl Sickles; Ambika Sohal; Kathleen Ruehle; Christian Lynch; Lei Zhang; David L Porter; Selina Luger; Chuanfa Guo; Hong-Bin Fang; William Blackwelder; Kim Hankey; Dean Mann; Robert Edelman; Carl Frasch; Bruce L Levine; Alan Cross; Carl H June
Journal:  Nat Med       Date:  2005-10-16       Impact factor: 53.440

8.  IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells.

Authors:  Mojgan Ahmadzadeh; Paul A Antony; Steven A Rosenberg
Journal:  J Immunother       Date:  2007-04       Impact factor: 4.456

9.  Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia.

Authors:  Claudia R Ruprecht; Marco Gattorno; Francesca Ferlito; Andrea Gregorio; Alberto Martini; Antonio Lanzavecchia; Federica Sallusto
Journal:  J Exp Med       Date:  2005-06-06       Impact factor: 14.307

10.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.

Authors:  Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas C Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2005-10-03       Impact factor: 14.307

View more
  13 in total

Review 1.  Evaluation of current cancer immunotherapy: hemato-oncology.

Authors:  Christopher S Hourigan; Hyam I Levitsky
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

2.  Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions.

Authors:  Matthias Piesche; Vincent T Ho; Haesook Kim; Yukoh Nakazaki; Michael Nehil; Nasser K Yaghi; Dmitriy Kolodin; Jeremy Weiser; Peter Altevogt; Helena Kiefel; Edwin P Alyea; Joseph H Antin; Corey Cutler; John Koreth; Christine Canning; Jerome Ritz; Robert J Soiffer; Glenn Dranoff
Journal:  Clin Cancer Res       Date:  2014-12-23       Impact factor: 12.531

3.  Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors.

Authors:  Joshua D Brody; Matthew J Goldstein; Debra K Czerwinski; Ronald Levy
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

4.  Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation.

Authors:  Ian Horkheimer; Michael Quigley; Jiangao Zhu; Xiaopei Huang; Nelson J Chao; Yiping Yang
Journal:  Blood       Date:  2009-03-11       Impact factor: 22.113

5.  Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.

Authors:  Vincent T Ho; Matthew Vanneman; Haesook Kim; Tetsuro Sasada; Yoon Joong Kang; Mildred Pasek; Corey Cutler; John Koreth; Edwin Alyea; Stefanie Sarantopoulos; Joseph H Antin; Jerome Ritz; Christine Canning; Jeffery Kutok; Martin C Mihm; Glenn Dranoff; Robert Soiffer
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-26       Impact factor: 11.205

Review 6.  Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation.

Authors:  Kirsten M Williams; Ronald E Gress
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

7.  Ineffective vaccination against solid tumors can be enhanced by hematopoietic cell transplantation.

Authors:  Alexander Filatenkov; Antonia M S Müller; William Wei-Lin Tseng; Sussan Dejbakhsh-Jones; Daniel Winer; Richard Luong; Judith A Shizuru; Edgar G Engleman; Samuel Strober
Journal:  J Immunol       Date:  2009-11-04       Impact factor: 5.422

8.  Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.

Authors:  Ute E Burkhardt; Ursula Hainz; Kristen Stevenson; Natalie R Goldstein; Mildred Pasek; Masayasu Naito; Di Wu; Vincent T Ho; Anselmo Alonso; Naa Norkor Hammond; Jessica Wong; Quinlan L Sievers; Ana Brusic; Sean M McDonough; Wanyong Zeng; Ann Perrin; Jennifer R Brown; Christine M Canning; John Koreth; Corey Cutler; Philippe Armand; Donna Neuberg; Jeng-Shin Lee; Joseph H Antin; Richard C Mulligan; Tetsuro Sasada; Jerome Ritz; Robert J Soiffer; Glenn Dranoff; Edwin P Alyea; Catherine J Wu
Journal:  J Clin Invest       Date:  2013-08-05       Impact factor: 14.808

9.  Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD.

Authors:  Ana C Alho; Haesook T Kim; Marie J Chammas; Carol G Reynolds; Tiago R Matos; Edouard Forcade; Jennifer Whangbo; Sarah Nikiforow; Corey S Cutler; John Koreth; Vincent T Ho; Philippe Armand; Joseph H Antin; Edwin P Alyea; Joao F Lacerda; Robert J Soiffer; Jerome Ritz
Journal:  Blood       Date:  2015-12-15       Impact factor: 22.113

10.  Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients.

Authors:  Ana Brusic; Ursula Hainz; Martha Wadleigh; Donna Neuberg; Mei Su; Christine M Canning; Daniel J Deangelo; Richard M Stone; Jeng-Shin Lee; Richard C Mulligan; Jerome Ritz; Glenn Dranoff; Tetsuro Sasada; Catherine J Wu
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.